Trial · NCT06001788
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT06001788, Phase 1, Recruiting, Kura Oncology, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia. Trials, record NCT06001788. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06001788
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- NCT number
- NCT06001788
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 171 participants, estimated
- Lead sponsor
- Kura Oncology, Inc.
- Conditions
AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar, NPM1 Mutation, MLL Rearrangement, Leukemia, Acute Myeloid Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Acute Leukemia, Neoplasms by Histologic Type
- Interventions
- Ziftomenib, Fludarabine, Idarubicin, Cytarabine, Gilteritinib, Granulocyte colony-stimulating factor
- First posted
- 2023-08-21
- Last updated
- 2026-08-20
Source ClinicalTrials.gov
Registered outcomes22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of dose limiting toxicities (DLTs) per dose level | During the first 28 days of ziftomenib in combination with SOC treatment (1 cycle) | Assessed by the NCI-CTCAE v5.0 |
| Primary | Descriptive statistics of adverse events | First dose of ziftomenib up to and including 28 days after last dose of ziftomenib, or if the patient is lost to follow-up, whichever comes first | Assessed by the NCI-CTCAE v5.0 |
| Secondary | Complete remission (CR) rate for cohorts A-1, A-2, B-1, and B-2 | Up to 12 months following discontinuation of treatment | Assessed by ELN 2022 criteria |
| Secondary | Complete remission (CR) / Complete remission with partial hematologic recovery (CRh) rate for cohort A-3 | Up to 12 months following discontinuation of treatment | Assessed by ELN 2022 criteria |
| Secondary | Composite complete remission (CRc) rate | Up to 12 months following discontinuation of treatment | Assessed by ELN 2022 criteria |
| Secondary | Morphologic leukemia-free state (MLFS) rate | Up to 12 months following discontinuation of treatment | Assessed by ELN 2022 criteria |
| Secondary | OS | Up to 12 months following discontinuation of treatment | To assess overall survival |
| Secondary | 6-month OS | Up to 6 months following discontinuation of treatment | To assess proportion of patients alive at 6 months |
| Secondary | Median EFS | Up to 12 months following discontinuation of treatment | To assess median event free survival |
| Secondary | 6-month EFS | Up to 6 months following discontinuation of treatment | To assess 6-month event free survival |
1 to 10 of 22Source ClinicalTrials.gov
See all 22 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06001788
GET https://conductscience.org/api/trials/v1/NCT06001788/registered?page=2